The effects of antimalarial drugs on ventricular repolarization

American Journal of Tropical Medicine and Hygiene

Volumn 67, Issue 1, 2002, Pages 54-60

  Touze, J E ^a   Heno, P ^a   Fourcade, L ^a   Deharo, J C ^a   Thomas, G ^a   Bohan, S ^a   Paule, P ^a   Riviere, P ^a   Kouassi, E ^a   Buguet, A ^a  

^a LAVERAN MILITARY TEACHING HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; CHLOROQUINE; HALOFANTRINE; MEFLOQUINE; QUININE;

ADULT; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART ARRHYTHMIA; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CINCHONA PUBESCENS; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0036656069     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.67.54     Document Type: Article

References (35)

1. Cardiac effects of antimalarial treatment with halofantrine
2. Halofantrine associated ventricular fibrillation in a young woman with no predisposing QTc prolongation
3. Quinine may trigger torsades de pointes during astemizole therapy
4. Effect of mefloquine on electrocardiographic changes in uncomplicated falciparum malaria
5. Atrial flutter with 1:1 conduction after administration of the antimalarial mefloquine
6. Importance of lead selection in QT interval measurement
7. Impact of eletrocardiogram recording format on QT interval measurement and QT dispersion assessment
8. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: Definitions and mechanisms
9. The QT interval and drug-associated torsades de pointes
10. Measurement, interpretation and clinical potential of QT dispersion
11. Effects of antiarrythmic drugs on QT interval dispersion- Relationship to antiarrhythmic action and proarrhythmia
12. Changes in repolarization dynamicity and the assessment of the antiarrhythmic risk
13. Severe falciparum malaria
14. Will QT dispersion play a role in clinical decision making?
15. Dynamic analysis of the QT interval in long QT1 syndrome patients with a normal phenotype
16. Validation of an improved reversed-phase high-performance liquid chromatography assay with reductive electrochemical detection for the determination of artemisinin derivatives in man
17. Clinical pharmacokinetics of halofantrine
18. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria
19. Fatal neurotoxicity of artether and artemether
20. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria
21. Comparison of artemether and quinine in the treatment of severe falciparum malaria in south east Thailand
22. No evidence of cardiotoxicity during antimalarial treatment with artemether
23. Safety of artemisin and its derivatives, a review of published and unpublished clinical trials
24. The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the tropics to the Netherlands and France
25. Prolongation of the QT interval in African children treated for falciparum malaria
26. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome
27. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography
28. Effect of the antimalarial drug halofantrine in the long QT syndrome due to a mutation of the cardiac sodium channel gene SCN5A
29. Mechanism of cardiotoxicity of halofantrine
30. Circadian variations of QT interval dispersion with heart rate variability
31. QT interval, heart rate and ventricular arrhythmias
32. Effect of verapamil on QT interval dynamicity
33. Time and rate dependent alterations of the QT interval precede the onset of torsades de pointe in patients with acquired QT prolongation
34. Rate adaptation of QT intervals during and after exercise in children with congenital long QT syndrome
35. Arrhythmic death in the EMIAT trial: Role of ventricular repolarisation dynamicity as a new discriminant risk marker